yes. Functional limitations are absent or very mild in MCI (Stage 3) but expected mild AD (stage 4). That's why there is an ADCS-ADL-MCI version to better query subtle functional impairments for activities of daily living. That scale was used in the lecanemab study (which was 80% MCI/20% mild compared to Anavex 60/40).
Market Data 
Markets 
AI
